Notice of Intent to Publish a Funding Opportunity Announcement for Discovering Novel Targets: The Molecular Genetics of Drug Addiction and Related Co-Morbidities (R01)

Notice Number: NOT-DA-17-005

Key Dates
Release Date:  December 5, 2016

Estimated Publication Date of Announcement:  January 2017 
First Estimated Application Due Date:  February 2017 
Earliest Estimated Award Date:   September 2017
Earliest Estimated Start Date:  November 2017

Related Announcements

Issued by
National Institutes on Drug Abuse (NIDA)


The National Institutes on Drug Abuse (NIDA) intends to reissue a Funding Opportunity Announcement (FOA) to encourage applications for research on the on the identification, validation and functional characterization of loci, genetic variations and haplotypes associated with addiction and related co-morbidities.

This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. 

The FOA is expected to be published in January 2017 with an expected application due date in February 2017.

This FOA will utilize the R01 activity code. Details of the planned FOA are provided below.

Research Initiative Details

This FOA encourages applications for research projects that identify, validate and/or functionally characterize loci, genetic variations and haplotypes that are associated with vulnerability to addiction and that potentially inform the likelihood of responsiveness to treatment.  Applications that propose to examine intermediate phenotypes or endophenotypes to assess the molecular genetics of drug addiction, addiction vulnerability and/or their associated co-morbidities and how they are related to drug addiction are especially encouraged.  Also encouraged are genetic as well as computational and large-scale genomic approaches, which may include but are not limited to linkage, linkage disequilibrium, case-control or family-based studies, and integration of data from other databases that may supplement substance abuse genetics and genomics data.  Data may be collected from the general population, special populations, recent admixed populations, and/or animal models. Secondary data analysis of data collected from the general population, special populations, recent admixed populations, and/or animal models is also appropriate for this announcement.  Investigators are encouraged to include functional characterization, gene x gene interactions, gene x environment interactions, gene x environment x development interactions, pharmacogenetics, and non-human models, as appropriate.



Please direct all inquiries to:

Jonathan D. Pollock, Ph.D.
National Institute on Drug Abuse (NIDA)
Telephone: 301-435-1309